Compare · MANE vs NVO
MANE vs NVO
Side-by-side comparison of Veradermics Incorporated (MANE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MANE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 46.4x MANE ($4.04B).
- Over the past year, MANE is up 156.4% and NVO is down 40.8% - MANE leads by 197.2 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 10 for MANE).
- NVO has more recent analyst coverage (25 ratings vs 5 for MANE).
- Company
- Veradermics Incorporated
- Novo Nordisk A/S
- Price
- $96.55-1.86%
- $42.01-2.10%
- Market cap
- $4.04B
- $187.53B
- 1M return
- -7.73%
- -5.38%
- 1Y return
- +156.44%
- -40.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2026
- News (4w)
- 10
- 11
- Recent ratings
- 5
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MANE
- Needham initiated coverage on Veradermics with a new price target
- Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
- Veradermics to Present at Upcoming June Investor Conferences
- Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research
- Amendment: SEC Form SCHEDULE 13G/A filed by Veradermics Incorporated
- SEC Form D filed by Veradermics Incorporated
- Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
- SEC Form 10-Q filed by Veradermics Incorporated
- Veradermics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates